Net Sales at Rs 173.35 crore in December 2024 up 7.35% from Rs. 161.48 crore in 2023. EBITDA stands at Rs. 35.44 crore in 2024 up 16.69% from 30.37 crore. SMS Pharma shares closed at 198.54 on February 13, 2025 (NSE) and has given -28.77% returns over the last 6 months and 36.64% over last 12 months. SMS Pharmaceuticals Standalone Quarterly Results in Rs. Cr. Dec’24 Sep’24 Dec’23 Net Sales/Income from operations 173. 35 196.75 161. 48 Other Operating Income — — — Total Income From Operations 173.33 196.74 161.46 Other Income 2.13 1.30 1.49 P/L Before Int., Excpt. Items & Tax 26.74 24.55 22.36 Interest 4.20 4.61 5.95 P/l Before Exceptional Items & tax 22.53 19.94 16.41 Exceptional items — — — P/ l Before Tax 22.94 19.41 16.17 Equity Share Capital 8.47 8. 47 8.17 Reserves Excluding Revaluation Reserves — — — Equity Dividend Rate (%) — — – Per. shares (as a % of the total Share Cap. of the company)
